Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue

AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Deferred Revenue of -$28.10 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-11-08

  • AKEBIA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was -$7.98M.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$10.73M, a 117.46% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$9.39M.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$22.86M, a 114.54% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2017 was -$14.42M, a 107.31% decline from fiscal 2016.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2016 was $197.29M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2018-09-30-$7.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$18.71M
derived: sum of 2 quarters · filed 2018-11-08
-$28.10M
10-Q · filed 2018-11-08
-$50.97M
derived: sum of 4 quarters · filed 2018-11-08
2018-06-30-$10.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$20.12M
10-Q · filed 2018-08-08
-$42.99M
derived: sum of 3 quarters · filed 2018-08-08
-$75.13M
derived: sum of 4 quarters · filed 2018-11-08
2018-03-31-$9.39M
10-Q · filed 2018-05-09
-$32.26M
derived: sum of 2 quarters · filed 2018-05-09
-$64.40M
derived: sum of 3 quarters · filed 2018-11-08
-$2.95M
derived: sum of 4 quarters · filed 2018-11-08
2017-12-31-$22.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
-$55.01M
derived: sum of 2 quarters · filed 2018-11-08
$6.44M
derived: sum of 3 quarters · filed 2018-11-08
-$14.42M
10-K · filed 2018-03-12
2017-09-30-$32.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$29.31M
derived: sum of 2 quarters · filed 2018-11-08
$8.44M
10-Q · filed 2018-11-08
$165.73M
derived: sum of 4 quarters · filed 2018-11-08
2017-06-30$61.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
$40.59M
10-Q · filed 2018-08-08
$197.88M
derived: sum of 3 quarters · filed 2018-08-08
$197.88M
derived: sum of 4 quarters · filed 2018-08-08
2017-03-31-$20.87M
10-Q · filed 2018-05-09
$136.42M
derived: sum of 2 quarters · filed 2018-05-09
$136.42M
derived: sum of 3 quarters · filed 2018-05-09
$136.42M
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31$157.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12
$157.29M
derived: sum of 2 quarters · filed 2018-03-12
$157.29M
derived: sum of 3 quarters · filed 2018-03-12
$197.29M
10-K · filed 2018-03-12
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$0.00
derived: sum of 2 quarters · filed 2017-11-08
$40.00M
10-Q · filed 2017-11-08
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08
$40.00M
10-Q · filed 2017-08-08
2016-03-31$40.00M
10-Q · filed 2017-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33